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The Rous sarcoma virus protease displays a high de-
gree of specificity and catalyzes the cleavage of only a
limited number of amino acid sequences. This specific-
ity is governed by interactions between side chains of
eight substrate amino acids and eight corresponding
subsite pockets within the homodimeric enzyme. We
have examined these complex interactions in order to
learn how to introduce changes into the retroviral pro-
tease (PR) that direct it to cleave new substrates. Mu-
tant enzymes with altered substrate specificity and
wild-type or greater catalytic rates have been con-
structed previously by substituting single key amino
acids in each of the eight enzyme subsites with those
residues found in structurally related positions of hu-
man immunodeficiency virus (HIV)-1 PR. These individ-
ual amino acid substitutions have now been combined
into one enzyme, resulting in a highly active mutant
Rous sarcoma virus (RSV) protease that displays many
characteristics associated with the HIV-1 enzyme. The
hybrid protease is capable of catalyzing the cleavage of
a set of HIV-1 viral polyprotein substrates that are not
recognized by the wild-type RSV enzyme. Additionally,
the modified PR is inhibited completely by the HIV-1
PR-specific inhibitor KNI-272 at concentrations where
wild-type RSV PR is unaffected. These results indicate
that the major determinants that dictate RSV and HIV-1
PR substrate specificity have been identified. Since the
viral protease is a homodimer, the rational design of
enzymes with altered specificity also requires a thor-
ough understanding of the importance of enzyme sym-
metry in substrate selection. We demonstrate here that
the enzyme homodimer acts symmetrically in substrate
selection with each enzyme subunit being capable of
recognizing both halves of a peptide substrate equally.
Rational design of HIV-11 protease inhibitors as therapeutic
agents for AIDS will require a thorough understanding of the
molecular mechanisms that govern the complex interactions
between the enzyme and its substrates. This necessitates iden-
tification of key amino acids that determine substrate specific-
ity. To identify these critical residues, we have exploited dif-
ferences in structure and specificity between the related
proteases from Rous sarcoma virus (RSV) and HIV-1. Although
these two enzymes share a 30% amino acid identity and com-
mon overall topology (1, 2), they possess markedly different
substrate specificities. HIV-1 protease catalyzes the cleavage
not only of its own Gag and Gag-Pol polyprotein sequences but
also those of the native RSV protease (PR) substrates (3, 4). In
contrast, RSV PR has a more limited substrate range, cleaving
its own, but not HIV-1 PR, polyprotein sequences. To gain
insight into the basis for these differences, we identified pro-
tease residues located within 10 Å of a bound substrate posi-
tioned by analogy to x-ray crystal structures of HIV-1 PR-
inhibitor complexes (5). Alignment of the two enzyme
structures revealed that many amino acid residues in the RSV
substrate binding pockets are identical to those in the struc-
turally equivalent positions of HIV-1 protease. However, a
small number of structurally equivalent residues differ be-
tween the two proteins (Fig. 1). We hypothesized that these
amino acid differences contribute to the difference in substrate
preference between RSV and HIV-1 proteases. To test this idea,
a number of RSV protease mutants were constructed by site-
directed mutagenesis that replaced one or two of these RSV
residues with the structurally equivalent HIV-1 residues (3–6).
Many of these constructs were active and displayed partially
altered specificity for substrate selection at one or two of the
eight enzyme subsites. Consistent with this result, Sedlacek et
al. (7) also showed that some of these changes allow for partial
HIV-1-like specificity with modified peptide substrates. Re-
cently, several of these residues have been shown to be substi-
tuted in viral mutants that arise during the development of
drug resistance to HIV-1 protease inhibitors in clinical trials
with AIDS patients (8). For a review of the resistant pheno-
types, see Ref. 9. Changes in substrate preference obtained
when single amino acid substitutions were introduced into RSV
PR were sufficient to allow for some catalytic activity on pep-
tides that represented one or two HIV-1 polyprotein cleavage
sites (3–6). However, it became clear that because subsites
were acting somewhat independently in substrate selection,
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multiple amino acid substitutions would be required to affect a
complete change in enzyme specificity. In this report, multiple
amino acid changes in enzyme subsites have been combined
into one construct and shown to impart substantial HIV-1-like
behavior upon the RSV PR. Moreover, a covalently linked
dimer PR was used to demonstrate that the symmetric sub-
units of the enzyme recognize both halves of a substrate
equally.
EXPERIMENTAL PROCEDURES
Protease Assay—PR activity was assayed in a volume of 25 ml of 100
mM sodium phosphate, pH 5.9, 2.4 M sodium chloride, 0–320 mM peptide
substrate, and 50–500 ng of PR. Reactions were initiated by the addi-
tion of protease, incubated at 37 °C for 3–15 min, and stopped by the
addition of 300 ml of 0.5 M sodium borate, pH 8.5. Twenty ml of 0.05%
(w/v) of fluorescamine was added. Relative fluorescence intensity was
measured on a Perkin-Elmer LS-50B luminescence spectrophotometer
using an excitation wavelength of 386 nm and an emission wavelength
of 477 nm. The concentration of peptide substrate was determined by
amino acid composition analysis. Each activity measurement repre-
sents the mean of at least three independent experiments. In each case,
the standard error for all experiments did not exceed 20% of the value
reported. Kinetic constants were determined using the assay described
above. Initial rate data from substrate saturation curves were fit to the
Michaelis-Menten equation using the NFIT program (5). Correlation
coefficients of the fit were greater than 0.98, and the standard deviation
of the constants reported was ,20%.
Peptides—Peptide substrates 9–12 amino acids in length were syn-
thesized, based on cleavage sites in Gag and Gag-Pol polyprotein pre-
cursors from RSV and HIV-1. These peptides include the 8 amino acids,
P4-P49, required for efficient and specific cleavage by the retroviral
protease. These residues interact with a unique array of amino acids in
the protease which form the S4-S49 subsites of the substrate binding
pocket. Peptides were synthesized with an amino-terminal proline res-
idue to prevent uncleaved substrate from reacting with fluorescamine.
Peptides were solubilized in 1 mM dithioerythritol, and their concentra-
tions were determined by quantitative amino acid composition analysis.
Plasmid Construction and Mutagenesis—The PR I42D,I44V was con-
structed by our previously published mutagenesis procedure (4).
Briefly, oligodeoxynucleotide 59- GACTCTGGAGCGGACACCGTCA-
TATCAGAGGAGGAT-39 was annealed to PvuI linearized PR I44V and
BglII/AccI gapped PR. PR I42D,I44V clones were screened for the
presence of a new AspI site. PR I42D,I44V,M73V,A100L was con-
structed by ligating a dephosphorylated 2.6-kb EcoRI/AccI fragment
from PR I42D,I44V to a 0.6-kb EcoI/AccI fragment from PR M73V,
A100L (4). Clones were screened by digestion with AspI (I42D,I44V),
SfuI (M73V), and SpeI (A100L). Finally, PR I42D,I44V,M73V,A100L,
V104T,R105P,G106V, S107N was constructed by a three-way ligation
with a 2.3-kb BglII/BssHII fragment from PR, a 0.6-kb BglII/AluI
fragment from PR I42D,I44V, and a 0.3-kb AluI/BssHII fragment from
PR V104T,R105P, G106V,S107N (4). Clones were screened for the pres-
ence of an AspI site (I42D,I44V), SfuI and SpeI sites (M73V,A100L), and
an AgeI site (V104T,R105P,G106V,S107N). The protease gene from the
above construct was also amplified using PCR with an upstream primer
that included a BamHI site followed by a nucleotide sequence coding for
a bovine factor Xa cleavage site. The downstream primer included a
HindIII site at the carboxyl end of the protease sequence. This product
was then cloned into the expression plasmid p6HRT (S. F. J. LeGrice,
Case Western Reserve University, Cleveland, OH) between the BamHI
andHindIII sites and replaced the HIV reverse transcriptase gene with
the mutant RSV protease gene. The S38T mutation was then added to
this construct using standard PCR mutagenesis procedures (4). Muta-
tions were confirmed by sequencing. The final RSV(S9) has the follow-
ing substitutions: PR S38T, I42D, I44V, M73V, A100L, V104T, R105P,
G106V, and S107N. The I42D,I44V mutations were also introduced into
the upstream or amino-terminal subunit of the dimer by ligating to-
gether the 220-base pair StuI-EcoRI fragment from the wild-type RSV
covalently linked PRGGGGPR expression plasmid, the 2599-base pair
EcoRI-AccI fragment from the I42D,I44V monomer expression plasmid,
and the 820-base pair StuI-AccI fragment from the linked dimer ex-
pression plasmid. The I42D,I44V mutation was introduced into the
downstream subunit by using PCR techniques to amplify the entire
I42D,I44V gene from the monomer expression plasmid. The upstream
oligodeoxynucleotide for amplification contained a StuI restriction site
(59-CCCGGCGGCGGAGGCCTAGCGATGACAATGGAACATAAAGAT-
39). The downstream oligodeoxynucleotide annealed at position 700 on
the monomer expression plasmid (59-AGCTGTGACCGTCTC-39). This
PCR amplified product was digested with BssHII and StuI and ligated
into the wild-type linked-dimer plasmid between the BssHII and StuI
sites.
Purification of AMV and HIV-1 Proteases—AMV protease was puri-
fied directly from virus particles as described previously (10). Intact
AMV was obtained from Molecular Genetic Resources (Tampa, FL).
HIV-1 protease was expressed in Escherichia coli and refolded from the
inclusion body fraction as described previously (11).
Purification of Wild-type and Mutant Linked-dimer RSV Proteases—
Bacterially expressed RSV wild-type and mutant linked-dimer, as well
FIG. 1. Schematic representation of the RSV NC-PR substrate, PAVSLAMT, from P4 to P4* in the S4-S4* subsites of PR. The relative
size of each subsite is indicated approximately by the area enclosed by the curved line around each substrate side chain. Protease residues forming
the subsites are shown for those that differ between the RSV and HIV-1 PRs. RSV PR residues are shown outside the parentheses, whereas the
HIV-1 PR residues are shown within the parentheses. Most of the residues contribute to more than one adjacent subsite and this is indicated by
the relative positions of the labels.
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as the I42D,I44V nonlinked homodimer proteases, were prepared from
E. coliMC1061 transformed with the temperature-sensitive l-cI repres-
sor plasmid, pRK248cIts, as described previously (12).
Purification of Soluble Bacterially Expressed Wild-type and Mutant
RSV Proteases—RSV wild-type and RSV(S9) histidine-tagged proteases
were expressed in E. coli M15 pDM1.1. Cells were grown at 30 °C in 4
liters of YT media, pH 7.5, to A600 5 0.6. Isopropyl-b-D-thiogalactopy-
ranoside was added to 0.5 mM and protein induced in cells for 2.5 h.
Bacterial cells were pelleted, washed in 10 mM Tris, pH 8.0, 10 mM
EDTA, and suspended in 10 mM HEPES, pH 8.3. Cells were lysed by
addition of lysozyme to 67 mg/ml and viscosity was reduced by incuba-
tion with DNase I to 33 mg/ml in the presence of 4 mM MgCl2 at room
temperature for 30 min. Cell debris was pelleted by centrifugation, and
the clarified supernatant was passed over a 1-ml Ni-NTA (Qiagen,
Chatsworth, CA) column equilibrated with 10 mM HEPES, pH 8.3, and
washed with 10 mM HEPES, pH 8.3, 30 mM imidazole, 10% glycerol.
Protease was then eluted with 10 mM HEPES, pH 8.3, 250 mM imidaz-
ole. Imidazole was removed by dialysis against 2 liters of 10 mM
HEPES, pH 8.3, 1 mM b-mercaptoethanol at 4 °C overnight. The histi-
dine tag was removed from the fusion protein by treatment with 100 mg
of bovine factor Xa (Hematological Technologies, Essex Junction, VT) in
10 mM HEPES, pH 8.3, 0.1 M NaCl, and 1 mM CaCl2. Cleavage was
monitored by separation of the proteins by SDS-PAGE and was usually
complete after 6-h incubation at room temperature. At this point the
RSV protease was maximally active and possessed the native sequence
at its amino terminus. The native PR was purified by passing the
digested enzyme preparation through a fresh Ni-NTA column, equili-
brated with 10 mM HEPES, pH 8.3. The cleaved PR now eluted from the
affinity resin with 30 mM imidazole. This eluted protease was contam-
inated with factor Xa, which was subsequently removed by treatment
with immobilized benzamidine (Pharmacia Biotech Inc., Uppsala, Swe-
den). Alternatively, biotinylated Factor Xa (Boehringer Mannheim) was
removed with immobilized streptavidin. The final yield of active puri-
fied PR is about 2 mg. The RSV protease is greater than 95% pure as
judged by SDS-PAGE (Fig. 2). Note that viral AMV and bacterially
expressed RSV protease differ in primary structure by only two amino
acids and are biochemically indistinguishable.
RESULTS AND DISCUSSION
Bacterial Expression and Purification of Soluble RSV
PR—We sought to develop a method of purifying active bacte-
rially expressed RSV PR that could be used for substrate spec-
ificity and structural studies. The earlier method of purifying
PR from inclusion bodies yielded pure enzyme, but had a rel-
atively low specific activity. While this activity was sufficient
for specificity studies, these preparations did not crystallize. To
avoid denaturation and refolding of PR, we developed a method
to purify recombinant PR from the soluble fraction of bacterial
cell extracts. A polyhistidine sequence was added to the amino
terminus of the PR to allow for efficient and rapid purification
of enzyme (Fig. 2, lane 2). The specific activity of the histidine-
tagged fusion PR was 5% that of AMV PR isolated directly from
virions. However, when the polyhistidine sequence was re-
moved by treatment with factor Xa (Fig. 2, lane 4), leaving the
native NH2-terminal sequence, active RSV protease was ob-
tained with a specific activity 75–100% that of the enzyme
purified from virus. Factor Xa was removed from the PR prep-
aration by affinity chromatography using immobilized benza-
midine as described under “Experimental Procedures.” The
resultant protein is greater than 95% pure as analyzed by
SDS-PAGE (Fig. 2, lane 5). One contaminating protein band
was detected that migrates slower than PR; it may have re-
sulted from limited cleavage of PR at an alternate internal
factor Xa site or could represent a bacterial protein. The pres-
ence of this band does not affect protease activity, and these
preparations are of a sufficient purity to form crystals suitable
for structural studies. A second construct was made which
FIG. 2. Bacterial expression and purification of RSV PR. RSV
PR (wild-type) was expressed and purified as described under “Exper-
imental Procedures.” Soluble extract from induced cells (lane 1) was
passed over a Ni-NTA column. PR was eluted with a 250 mM imidazole
wash (lane 2). The NH2-terminal histidine tag was removed by treat-
ment with bovine factor Xa. After treatment, the PR was applied to the
Ni-NTA column which was washed with buffer (lane 3) and then 30 mM
imidazole wash (lane 4). Factor Xa was then removed by treatment with
immobilized benzamidine (lane 5). Protein molecular mass markers
143, 97, 50, 35, 30, and 22 kDa are shown (lane M). The molecular mass
of native RSV PR monomer is 13.5 kDa.
FIG. 3. Stereo representation of the
RSV PR containing nine amino acid
substitutions that influence the se-
lection of substrate and catalytic
rate. Amino acids important for sub-
strate selection and catalytic rate by RSV
protease are shown by ball and stick
structures in a crystal structure model of
a homodimeric enzyme. These include
RSV PR positions 38, 42, 44, 73, 100, 104,
105, 106, and 107. The RSV NC-PR pep-
tide substrate is shown in the active site
with thick lines. The figure was prepared
with MOLSCRIPT (15).
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expresses an altered RSV PR, referred to as RSV PR(S9). This
PR has nine substituted residues, including S38T, I42D, I44V,
M73V, A100L, V104T, R105P, G106V, and S107N. The
RSV(S9) PR was expressed, purified from the soluble fraction,
and activated as described for the wild type PR.
Changing the Specificity of the RSV PR—We have combined
nine mutations into the RSV PR gene that introduce specific
amino acid substitutions into the substrate binding pocket. The
position of these residues relative to the RSV NC-PR peptide
substrate is shown in Fig. 3. The S38T substitution was added
to the PR, since we have confirmed that this mutation, by itself,
increased the rate of catalytic activity of PR about 2-fold. When
combined into a single enzyme, these multiple substitutions
allow the protease to cleave four HIV-1 peptide substrates at
initial rates more than 100-fold greater than wild-type RSV
PR. Steady state kinetic data obtained from substrate satura-
tion curves show that the RSV(S9) protease has Km values
determined with the HIV-1 PR substrates that are 2–8-fold
higher than the corresponding values for HIV-1 PR. The Km
values for HIV-1 PR ranged from 30 to 100 mM, while those for
RSV(S9) PR ranged between 111 and 366 mM for the same
substrates (Table I). Note that the Km values for AMV PR on
the HIV-1 PR substrates could not be measured, because these
peptides are not cleaved to any significant extent. Sites of
cleavage were established by NH2-terminal amino acid analy-
sis of the product peptides (Ref. 4 and data not shown). The
overall catalytic efficiencies (kcat/Km) of RSV(S9) PR are 1.1–
4.9-fold lower than those determined with the HIV-1 PR. How-
ever, substrates that are cleaved most efficiently by HIV-1
protease are also those that are cleaved most efficiently by the
RSV(S9) mutant. With the RSV NC-PR reference substrate,
the RSV PR(S9) enzyme resembles the HIV-1 PRmore than the
parental RSV enzyme. Its specific activity on this substrate is
approximately 2.5 times greater than the wild-type enzyme. Its
overall catalytic efficiency (kcat/Km) is about 10 times higher
due primarily to a sharp decrease in the Km for the NC-PR
substrate. These results demonstrate that the modest specific-
ity changes introduced by each of the single mutations can be
combined to produce a highly active enzyme with a signifi-
cantly altered substrate preference. Furthermore, by combin-
ing all nine amino acid substitutions into one enzyme, cleavage
of the HIV-1 RT-IN, CA-NCa, and NC-p6a substrates was
considerably greater than that observed with enzymes contain-
ing the same mutations as either single or double substitutions
(4). This is to be expected, as many of these residues contribute
to more than one enzyme subsite and all have to be changed in
order to affect a complete change in specificity.
There are two additional indicators that the RSV(S9) PR has
substantial HIV-1 PR character. First, it is inhibited effectively
by the previously described nanomolar HIV-1 PR inhibitor,
KNI-272 (14). At inhibitor concentrations which completely
block activity of both HIV-1 PR and RSV(S9) PR, wild-type
AMV PR is unaffected (Fig. 4). Second, the salt dependence of
RSV(S9) PR is closer to that observed with HIV-1 PR than that
with RSV PR (Fig. 5). For instance, in the presence of 1 M NaCl,
HIV-1 PR has 100%, RSV(S9) PR has greater than 60%, and
the AMV PR has less than 20% of their respective maximal
activities with the NC-PR peptide substrate.
While RSV(S9) PR displays substantial HIV-1 PR-like sub-
FIG. 4. Inhibition of AMV, RSV(S9), and HIV-1 PRs by the
HIV-1 PR inhibitor KNI-272. Ten ng of AMV (E), RSV(S9) (å), or
HIV-1 PR (M) was incubated with 100 mM NC-PR peptide and various
concentrations of KNI-272. Activity is expressed as a percentage of
activity in the absence of inhibitor.
FIG. 5.Effect of salt on the activity of AMV, RSV(S9), and HIV-1
PRs. PR activity was measured as described in the legend to Fig. 4,
except that the amount of the NaCl in the assay was varied as indi-
cated. M, HIV-1 PR; å, RSV(S9) PR; E,AMV PR.
TABLE I
Comparison of steady state kinetic activity by AMV, HIV-1, and
RSV(S9) proteases on peptide substrates
Varying concentrations of peptide substrates were incubated with
different PRs, and the extent of cleavage was determined using the
fluorescence assay described under “Experimental Procedures.”
Protease Substratea Km kcat kcat/Km
mM min21 min21 mM21
AMV RSV NC-PR 67 25 0.4
HIV-1 RSV NC-PR 6 14 2.3
RSV (S9) RSV NC-PR 6 43 7.2
HIV-1 HIV RT-IN 32 161 5.0
HIV CA-NCb 30 207 6.9
HIV CA-NCa 44 50 1.1
HIV NC-p6a 100 33 0.3
RSV (S9) HIV RT-IN 111 492 4.4
HIV CA-NCb 132 179 1.4
HIV CA-NCa 366 98 0.3
HIV NC-p6a 283 17 0.1
a The amino acid sequences of the peptide substrates are as follows:
RSV NC-PR, PPAVS-LAMTMRR; HIV-1 RT-IN, PARVL-FLDGRR;
HIV-1 CA-NCb, PATIM-MQRERR; HIV-1 CA-NCa, PARVL-AE-
AMRR; HIV-1 NC-p6a, PGNF-LQSRR. These amino acid sequences
are presented in one letter notation with the amino terminus to the left.
Specific PR cleavage sites are indicated by hyphens with the natural
sequence in bold letters. Nonboldface Arg residues were added to the
substrate to improve solubility, and a Pro residue was added to the
amino terminus to prevent the starting substrate from reacting with
fluorescamine. Neither modification affects PR activity.
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FIG. 6. Schematic representation of the effects of asymmetric S2 subsite PR mutations on cleavage of NC-PR peptide substrates
with leucine substitutions in the P2 and/or P2* positions. The noncovalently linked PR is indicated at the top of the figure by the presence
of two separated subunits (A and B). The covalently linked PR is indicated by subunits connected with the triangle at the top (C and D). The
wild-type S2 and S29 subsites are represented by the small half-circles. S2 and S29 subsites with the I42D,144V specificity altering substitutions
are represented by the large half-circles. A diagrammatic representation of the NC-PR peptide substrate is depicted below with wild type residues
in P2 and P29 denoted by small circles and Leu substitutions by the large circles.
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strate specificity and kinetics, complete conversion to HIV-1 PR
specificity has not been reached. This is seen by differences in
activity between HIV-1 and RSV(S9) proteases with HIV-1
substrates (kcat/Km values in Table I), differences in effective-
ness of the KNI-272 inhibitor (Fig. 4), and salt dependence for
activity (Fig. 5). One of several possible reasons for this is that
the nine amino acids substituted into the RSV PR influence
substrate amino acid selection primarily in six of the eight
enzyme subsites, S3 to S39. These substitutions have limited
influence on substrate selection in the S4 and S49 subsites. An
additional mutation that deletes RSV PR residues 61–63, at
the base of the enzyme flaps, alters preference for amino acids
interacting with the S4 and S49 subsites to resemble that of
HIV-1 PR (4). These residues are unique to the RSV enzyme,
which has larger flaps than the HIV-1 PR. Unfortunately,
when this deletion was combined with other RSV PR muta-
tions, it produced an inactive enzyme. It seems likely that the
removal of these residues caused a conformational change
which was not tolerated in the context of the other mutations.
Additional changes in the RSV(S9) PR will probably have to be
made in order to accommodate the S4 and S49 deletions.
Analysis of RSV(S9) PR activities provides some insight into
protease substrate recognition. One can explain the varied
steady state kinetic data with different HIV-1 substrates in
Table I by the fact that the peptide substrates each have
markedly different amino acid sequences, and the (S9) muta-
tions do not affect cleavage at each site equally. Thus, strong
interactions between the enzyme and the CA-NCb, CA-NCa,
and NC-p6a substrates may depend not only on differences in
the S3 to S39 subsites, but also on the S4 and S49 subsites that
were not altered in the RSV PR(S9). In contrast, RT-IN and
inhibitor KNI-272 interactions do not seem to depend on
changes in the S4 and S49 subsites.
Asymmetry Is Introduced in the PR Homodimer by Substrate
Binding—The active retroviral PR is a homodimer. Therefore,
each of the amino acid substitutions that has been shown to
influence selection has been, in effect, a double substitution
that alters specificity of at least two subsites formed by the two
subunits on opposite sides of the enzyme. In order to examine
the effect of substitutions in individual subunits, a catalytically
active protease dimer covalently linked by four glycine residues
between the carboxyl terminus of one subunit and the amino
terminus of the second subunit was prepared as described
previously (12). This construct was then used to introduce the
double substitution, I42D,I44V, into the separate PR subunits
designated N or C for NH2-terminal half or COOH-terminal
half as depicted in Fig. 6, A–D. These substitutions were chosen
because they confer a change in specificity for substrate amino
acids at the S2 and S29 subsites. A homodimeric, noncovalently
linked enzyme with the same amino acid substitutions in both
subunits is capable of cleaving efficiently RSV NC-PR peptide
substrates containing Leu substituted for either P2 Val or P29
Ala, whereas the wild-type enzyme cleaves these substrates
poorly (Fig. 7). The I42D,I44V(N) mutation introduces the ap-
propriate changes into the coding sequences of the upstream
subunit in the plasmid that expresses the linked-dimer. As
expected, the resultant enzyme is capable of cleaving the
NC-PR peptide substrate with the large Leu in P2 (Fig. 7),
because the corresponding S2 subsite is made larger by the
mutations. Additionally, the I42D,I44V(N) dimer also cleaves a
peptide with Leu at the P29 position efficiently. These results
suggest that a subsite containing a single mutation can accom-
modate either the P2 or the P29 amino acids allowing for the
cleavage of a substrate bound in two different orientations, as
depicted in Fig. 6, A–D. To verify that the enzyme is function-
ally symmetric, the same I42D,I44V substitutions were intro-
duced into the carboxyl-terminal half of the linked-dimer. The
enzyme produced from this clone also cleaves both the P2 Leu
and the P29 Leu-modified substrates with efficiencies equal to
those seen with the I42D,I44V(N) mutant (Fig. 7). In contrast,
a substrate that includes Leu in both the P2 and P29 positions
is cleaved efficiently only by the noncovalently linked PR that
contains the 42 and 44 substitutions in both S2 and S29 simul-
taneously. Taken together, these results indicate that the RSV
protease homodimer is symmetric when not bound to a sub-
strate and that each enzyme subunit is capable of binding
equally to either half of an asymmetric substrate. This is con-
sistent with structural data which show that substrate-based
inhibitors can occur in two different conformations when bound
to the HIV-1 PR (13).
The results presented here demonstrate that amino acids
can be substituted at key residues in most of the enzyme
subsites that alter RSV PR specificity. The present construct
combined nine separate amino acid substitutions and produced
an RSV PR that cleaves peptide substrates representing HIV-1
gag and pol gene cleavage sites. Furthermore, by using a co-
valently linked PR dimer, we have demonstrated that key
amino acid residues can be changed in separate subunits to
produce an asymmetrically substituted enzyme. This strategy
can be used to create a PR, targeted to a new protein sequence,
in which each enzyme subunit is custom designed to bind
efficiently to one-half of the new substrate sequence. The re-
sulting enzyme will prefer one substrate orientation over the
reverse orientation. Finally, examination of structural differ-
ences between similar yet catalytically unique enzymes has
advanced our understanding in a way that would not have been
possible if each had been examined individually. This general
approach can be extended to many other protein families to
FIG. 7. Effects of S2 subsite substitutions in different subunits
of the PR dimer on cleavage of NC-PR substrates with amino
acid substitutions in the P2 and/or P2* positions. Changes in
protease substrate preference caused by substitutions in the S2 enzyme
subsite in either one or both subunits was determined. Enzyme activity
was measured using a RSV NC-PR peptide substrate with Leu substi-
tuted in P2 (PPALS-LAMTMRR) (gray boxes), in P29 (PPAVS-LLMT-
MRR) (black boxes), or in both P2 and P29 (PPALS-LLAMTMRR) (white
boxes). Activity is expressed as a percentage relative to the initial rate
of cleavage of the wild-type NC-PR peptide substrate and was measured
using the fluorescamine assay (4). PRGGGGPR is a wild-type RSV PR
that has the two subunits of the homodimer linked with four Gly
residues. RSV PR (I42D,I44V) is a noncovalently linked protease ho-
modimer with substitutions in the S2 and S29 subsites. RSV
PRGGGGGPR (I42D,I44V(N)) and RSV PRGGGGGPR (I42D,I44V (C))
are covalently linked homodimers with asymmetric substitutions in
either the amino or carboxyl subunits as indicated by the N and C,
respectively. The activity data are summarized in Fig. 6, A–D.
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identify key enzyme residues that mediate specific protein-
substrate and protein-protein interactions.
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